Skip to content
Clinical Trials – home

Asklepios Kliniken Hamburg GmbH

Verifiedinfo

Germany Eissendorfer Pferdeweg 52, Heimfeld, 21075 Hamburg, Germany

  • 63 trials recruiting
  • Colorectal cancer metastatic · Non-small cell lung cancer · Plasma cell myeloma
  • Adults and children

About Specializations

Asklepios Kliniken Hamburg GmbH in Hamburg, Germany specialises in clinical trials of conditions such as Colorectal cancer metastatic, Non-small cell lung cancer, Plasma cell myeloma, Colorectal cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Oncology

The medical center is at the forefront of research in hematologic oncology, focusing on innovative treatments for conditions such as mantle cell lymphoma and multiple myeloma. The center's trials explore the efficacy of novel drug combinations and stem cell transplantation techniques.

  • Autologous Transplantation in Mantle Cell Lymphoma
  • Elotuzumab and Carfilzomib in Multiple Myeloma
  • Isatuximab in High-Risk Multiple Myeloma

These studies aim to improve failure-free survival and progression-free survival in patients, setting new standards in treatment protocols.

Thoracic Oncology

Specializing in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), the center conducts pivotal trials to assess the safety and efficacy of targeted therapies and immunotherapies. These studies are crucial for advancing treatment options for lung cancer patients.

  • Dato-DXd in Advanced NSCLC
  • Zipalertinib for EGFR Mutations
  • JDQ443 in KRAS G12C-mutated NSCLC

Research efforts focus on improving progression-free survival and overall survival, offering hope for better patient outcomes.

Gastrointestinal Oncology

The center is a leader in gastrointestinal oncology, with a strong emphasis on developing new treatments for pancreatic cancer and colorectal cancer. Innovative trials are underway to evaluate the effectiveness of combination therapies and novel agents.

  • Tumor Treating Fields in Pancreatic Cancer
  • Amivantamab in Colorectal Cancer
  • Pelareorep in Advanced GI Tumors

These studies aim to enhance disease control rates and overall survival, contributing to significant advancements in the field.

Genitourinary Oncology

Focusing on renal cell carcinoma and urothelial carcinoma, the center's research explores the potential of immunotherapy and targeted treatments. These efforts are crucial for improving therapeutic outcomes in genitourinary cancers.

  • Pembrolizumab in Renal Cell Carcinoma
  • Nivolumab in Urothelial Cancer
  • V940 in High-Risk RCC

Research initiatives aim to enhance disease-free survival and overall survival, offering new hope for patients.

Cardiovascular Research

The center is pioneering research in cardiovascular diseases, with a focus on innovative treatments for conditions such as hypertension and calcific aortic valve stenosis. These studies are essential for developing new therapeutic strategies.

  • Renal Denervation in Hypertension
  • Pelacarsen in Aortic Valve Stenosis

Research efforts are directed towards improving patient outcomes and advancing the understanding of cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Eissendorfer Pferdeweg 52, Heimfeld21075 HamburgGermany
Recruiting now
63 trials
Conditions studied
88
Partner status
Verified

More sites in HamburgGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

122 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.